BridGene Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, BridGene Biosciences sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

BridGene Biosciences: 1 sponsored US clinical trial, 1 recruiting.

BridGene Biosciences sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mesothelioma, with 1 trials.

Mid-pack sponsor footprint

BridGene Biosciences is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Phase Distribution

PhaseTrial count
Phase 1 1

What is open in the BridGene Biosciences pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Mesothelioma (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

BridGene Biosciences: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

BridGene Biosciences sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share BridGene Biosciences1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
BridGene Biosciences sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

BridGene Biosciences sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this BridGene Biosciences page

1 registered trials is a research-attention snapshot, not an endorsement of BridGene Biosciences or any single study.

  • 1 of BridGene Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Mesothelioma is the condition BridGene Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Mesothelioma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

BridGene Biosciences pipeline card: 1 registered trials from official public datasets.Report a data error.